Lionco Pharm Grp Co Ltd Working Capital to Net Assets Ratio
Lionco Pharm Grp Co Ltd working capital to net assets ratio. Lionco Pharm Grp Co Ltd (603669) has a Working Capital to Net Assets ratio of 15.4% as of June 2026. Working capital of CN¥98.96 Million (current assets of CN¥557.03 Million minus current liabilities of CN¥458.06 Million) is measured against net assets of CN¥641.40 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Lionco Pharm Grp Co Ltd (2011–2025)
Working capital to net assets ratio of Lionco Pharm Grp Co Ltd from 2011 to 2025. This chart shows how Lionco Pharm Grp Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 15.4%, reflecting working capital of CN¥98.96 Million against net assets of CN¥641.40 Million CNY. Explore Lionco Pharm Grp Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Lionco Pharm Grp Co Ltd Working Capital to Net Assets Ratio by Year (2011–2025)
Lionco Pharm Grp Co Ltd working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Lionco Pharm Grp Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 603669 total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 7.5% | CN¥46.80 Million | CN¥620.28 Million | CN¥525.38 Million | CN¥478.58 Million | ▼ -40.2 pp |
| 2024 | 47.7% | CN¥367.30 Million | CN¥769.76 Million | CN¥586.61 Million | CN¥219.31 Million | ▼ -20.9 pp |
| 2023 | 68.6% | CN¥638.42 Million | CN¥931.04 Million | CN¥881.53 Million | CN¥243.11 Million | ▼ -4.5 pp |
| 2022 | 73.1% | CN¥829.62 Million | CN¥1.14 Billion | CN¥1.13 Billion | CN¥302.42 Million | ▼ -5.0 pp |
| 2021 | 78.1% | CN¥1.14 Billion | CN¥1.46 Billion | CN¥1.79 Billion | CN¥648.85 Million | ▼ -10.2 pp |
| 2020 | 88.3% | CN¥1.31 Billion | CN¥1.48 Billion | CN¥2.04 Billion | CN¥731.57 Million | ▲ +25.5 pp |
| 2019 | 62.8% | CN¥825.36 Million | CN¥1.31 Billion | CN¥1.23 Billion | CN¥400.70 Million | ▲ +3.2 pp |
| 2018 | 59.7% | CN¥822.09 Million | CN¥1.38 Billion | CN¥1.33 Billion | CN¥504.37 Million | ▼ -1.3 pp |
| 2017 | 61.0% | CN¥792.10 Million | CN¥1.30 Billion | CN¥1.13 Billion | CN¥340.06 Million | ▼ -1.7 pp |
| 2016 | 62.6% | CN¥732.37 Million | CN¥1.17 Billion | CN¥893.10 Million | CN¥160.73 Million | ▼ -3.2 pp |
| 2015 | 65.9% | CN¥737.29 Million | CN¥1.12 Billion | CN¥944.38 Million | CN¥207.09 Million | ▲ +61.5 pp |
| 2014 | 4.4% | CN¥16.48 Million | CN¥374.13 Million | CN¥184.27 Million | CN¥167.79 Million | ▼ -11.0 pp |
| 2013 | 15.4% | CN¥54.15 Million | CN¥351.02 Million | CN¥269.56 Million | CN¥215.41 Million | ▼ 0.0 pp |
| 2012 | 15.4% | CN¥36.47 Million | CN¥236.22 Million | CN¥160.50 Million | CN¥124.02 Million | ▼ -3.1 pp |
| 2011 | 18.6% | CN¥23.86 Million | CN¥128.55 Million | CN¥136.77 Million | CN¥112.91 Million | — |